Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIRTIVITY study of BI 1291583 in bronchiectasis
2024-518589-29-00Phase 3Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 49
01
Overview
Phase 3, randomised, double-blind trial in bronchiectasis comparing BI 1291583 with Placebo matching BI 1291583 (2 arms). Primary endpoint: Annualized rate of adjudicated pulmonary exacerbations. Planned start Aug 2025; status: authorised.
02
Drugs
verducatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on 2024-518589-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518589-29-00.